Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

ClinicalTrials.gov ID: NCT02603705

Public ClinicalTrials.gov record NCT02603705. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain

Study identification

NCT ID
NCT02603705
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Egalet Ltd
Industry
Enrollment
281 participants

Conditions and interventions

Interventions

  • Oxycodone extended-release Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 6, 2016
Primary completion
Jun 14, 2017
Completion
Jun 14, 2017
Last update posted
Mar 4, 2018

2016 – 2017

United States locations

U.S. sites
39
U.S. states
22
U.S. cities
38
Facility City State ZIP Site status
Site 334 Huntsville Alabama 35801
Site 328 Tucson Arizona 85712
Site 332 Jacksonville Florida 32257
Site 340 Miami Gardens Florida 33169
Site 320 Plantation Florida 33317
Site 302 Tampa Florida 33603
Site 315 Tampa Florida 33613
Site 310 Winter Haven Florida 33880
Site 316 Dawsonville Georgia 30534
Site 311 Marietta Georgia 30060
Site 336 Bloomington Illinois 61701
Site 345 Blue Island Illinois 60406
Site 304 Evansville Indiana 47714
Site 325 Valparaiso Indiana 46383
Site 321 Overland Park Kansas 66210
Site 342 Wichita Kansas 67205
Site 329 New Orleans Louisiana 70114
Site 326 Quincy Massachusetts 02169
Site 303 St Louis Missouri 63141
Site 306 Las Vegas Nevada 89119
Site 313 Belvidere New Jersey 07823
Site 346 Blackwood New Jersey 08012
Site 323 Hartsdale New York 10530
Site 338 Mooresville North Carolina 28117
Site 333 Cincinnati Ohio 45212
Site 343 Cleveland Ohio 44122
Site 308 Huber Heights Ohio 45424
Site 347 Kettering Ohio 45429
Site 335 Oklahoma City Oklahoma 73112
Site 312 Eugene Oregon 97401
Site 322 Duncansville Pennsylvania 16635
Site 324 Wyomissing Pennsylvania 19610
Site 344 Myrtle Beach South Carolina 29588
Site 314 Summerville South Carolina 29485
Site 341 New Tazewell Tennessee 37825
Site 318 Austin Texas 78731
Site 330 Dallas Texas 75231
Site 309 San Antonio Texas 78218
Site 331 West Jordan Utah 84088

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02603705, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 4, 2018 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02603705 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →